Newsgroup: it.economia.borsa
Titolo: CELL T. (in vendita!)

sono in asta (0,6) per la vendita ultima trance meglio non rischiare solo 
intraday d'ora in poi!!........ 

 intraday d'ora in poi!!........
che nella COSOB ci sia del marcio lo si sapeva ma oggi sono scandalosi! tu 
dimmi perche � sospesa da 2 ore sti delinquenti!!!   segna un +6 teorico 
assurda la sospensione cosi prolungata!!  fino ad 1 anno fa c'erano dei 
tempi precisi sulle sospensioni ora invece fanno quel cavolo che vogliono 
bhaaaaaaaaaaaaaaa 

 solo intraday d'ora in poi!!........
io aspetto gioved� la 4 trimestrale 2009
non chi mi aspetti un granch�, ma visto che sono in ballo... allora ballo

 ha scritto nel messaggio 
news:u1ecn.22862$Ua....@twister2.libero.it...

sei dentro a 0,84 ?
non potevi impostare peggior ingresso
tieni conto che loro giocano sempre sulle false aspettative che creano

 tieni conto che loro giocano sempre sulle false aspettative che creano
esatto e ieri hanno architettato perfettamente una falsa aspettativa al 
ribasso
per questo non mi sono messo sciort (e chi l'ha fatto, oggi si sta 
ricoprendo in fretta....)

 ha scritto nel messaggio 
news:Glecn.22880$Ua....@twister2.libero.it...

non puoi metterti short e lo sai
ieri la fed ha solo espresso tutta una serie di perplessit�

 ieri la fed ha solo espresso tutta una serie di perplessitï¿œ
la tossicita' non e' un problema..leggete pag 83
At the end of the treatment period in PIX301, doxorubicin equivalent 
exposure was significantly higher in the pixantrone group than in the 
comparator group (528 mg/m2 vs 331 mg/m2; p < 0.001, range 400 mg/m2 to 
 > 900 mg/m2). At similar exposure levels, doxorubicin is reported in 
the literature as associated with an incidence of CHF ranging from 26% 
to 48% (Swain 2003). In PIX301, CHF occurring during the study treatment 
period was
Briefing Document for Pixantrone NDA 22-481
Cell Therapeutics, Inc. Page 84
infrequent, not considered to be related to study drug in all but one 
case and, importantly, was not dependent on cumulative exposure.
Pixantrone permette dosaggi doppi rispetto alla doxorubicin e non causa 
accumulo.

LoZioPuparo ha scritto:

ho letto i dati dello Zevalin,,,, come tossicitï¿œ ï¿œ il doppio di pix,,,, 
eppure ï¿œ stato approvato

The pixantrone study failed, even using Cell Therapeutics' own statistical 
plan due to the low patient enrollment. In order for the pixantrone study to 
have been positive and statistically significant, the "p value" generated by 
the final analysis needed to be lower than 0.0096. The actual "p value" was 
0.021. 

Cell Therapeutics enrolled a large number of patients who didn't suffer from 
aggressive NHL, per the eligibility rules of the phase III study. Therefore, 
five pixantrone patients deemed to have a complete response by Cell 
Therapeutics were thrown out in the FDA's analysis. Likewise, one patient in 
the comparator arm was similar excluded.

The FDA, in it review, notes that, "Most patients were accrued outside of 
the U.S., with 8 patients accrued from 6 sites in the US." Wow! Only eight 
patients out of 140 total were enrolled in the U.S.
The FDA also states, "Of concern, no patients enrolled in the US attained a 
CR or CRu."

> ieri la fed ha solo espresso tutta una serie di perplessit�

Monday, the FDA raised serious questions about pixantrone's safety, noting 
that, "deaths, SAEs (serious adverse events), and grade 3-4 events were all 
more common on the pixantrone arm.
Moreover, three pixatrone pateints died to due to heart failure compared to 
a single patient in the study's comparator arm, according to the FDA's 
analysis.
The FDA goes on to state, "All of this suggests that pixantrone is indeed 
cardiotoxic, but no conclusions can be drawn concerning its toxicity 
relative to other anthracyclines/anthracenediones.